| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Feb, 2026 |
| Sales | 2,696,400 | 3,109,000 | 3,096,100 | 3,057,500 | 0 |
| Sales Growth | -13.27% | +0.42% | +1.26% | unch | unch |
| Net Income | -328,500 | -3,400 | 192,900 | 98,000 | 0 |
| Net Income Growth | -9,561.76% | -101.76% | +96.84% | unch | unch |
Fortrea Holdings Inc (FTRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fortrea Holdings Inc. is a provider of clinical development and patient access solutions to the life sciences industry. It provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea Holdings Inc. is based in DURHAM, N.C.
Fiscal Year End Date: 12/31